新诊断成人免疫性血小板减少症联合治疗是否有长期效果?
该分析纳入3项随机对照试验(地塞米松对比地塞米松联合利妥昔单抗2项,霉酚酸酯联合类固醇对比单用类固醇1项)和6项单臂试验(地塞米松联合利妥昔单抗±环孢素,地塞米松联合TPO受体激动剂±利妥昔单抗),评估新诊断成人免疫性血小板减少症联合治疗的长期效果。初始及短期应答率为50%-84%,1年以上应答率为47%-77%,但许多研究缺乏超过1-1.5年的长期随访,联合治疗下长期无治疗持续应答的新诊断患者数量尚不清楚,有待研究。
要点
- 新诊断成人免疫性血小板减少症标准一线治疗为类固醇±静脉注射免疫球蛋白,可有效提升血小板计数并减轻出血或出血风险。
- 联合治疗初始及短期应答率为50%-84%,1年以上应答率为47%-77%。
- 许多研究缺乏超过1-1.5年的长期随访,联合治疗下长期无治疗持续应答的新诊断患者数量尚不清楚,有待研究。
核心结论
- 联合治疗短期应答有前景,但许多研究缺乏超过1-1.5年的长期随访,联合治疗下长期无治疗持续应答的新诊断患者数量尚不清楚,有待研究。
研究设计与样本
- 分析纳入3项随机对照试验(2项地塞米松对比地塞米松联合利妥昔单抗,1项霉酚酸酯联合类固醇对比单用类固醇)和6项单臂试验(地塞米松联合利妥昔单抗±环孢素,地塞米松联合TPO受体激动剂±利妥昔单抗)。
主要发现
- 各研究中初始及短期应答率为50%-84%,1年以上应答率为47%-77%。
- 许多研究缺乏超过1-1.5年的长期随访。
关键数值与推荐
- 初始及短期应答率为50%-84%,1年以上应答率为47%-77%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 许多研究缺乏超过1-1.5年的长期随访。
- 联合治疗下长期无治疗持续应答的新诊断患者数量尚不清楚,有待研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In newly diagnosed (ND) adults with immune thrombocytopenia, standard first-line treatment (steroids ± IVIG) effectively raises platelet counts and mitigates bleeding or the risk thereof. In difficult-to-treat patients who fail first-line treatment, combination therapy may be appropriate; however, first- and second-line treatments could be combined at diagnosis to further improve initial platelet count and sustained off-treatment response in ND patients following the hypothesis that autoimmune responses are more malleable at diagnosis than later. Three randomised controlled trials (2 dexamethasone (dex) vs. dexamethasone + rituximab (ritux), 1 mycophenolate mofetil (MMF) + steroids vs. steroids alone) and six single-arm trials (dex + ritux ± ciclosporin and dex + TPO-RA ± ritux) were analysed to determine the effects of combining these therapies. Across the studies, initial and short-term responses were robust (50%-84%) with responses past 1 year ranging from 47% to 77%. While short-term responses were promising, many studies lacked a longer follow-up past 1-1.5 years. The amount of ND patients who would have entered sustained response off therapy long term with no treatment/steroids only, as well as with combination therapy, is thus unknown and remains to be investigated.
引用
- Peko GA, Bussel JB. Are there long-term effects of combination therapy for newly diagnosed adults with ITP? Br J Haematol. 2025. PMID: 41387255. doi:10.1111/bjh.70255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。